TNF Inhibitor denied as experimental or investigational by Anthem Blue Cross?

Anthem CA uses CarelonRx PBM. Adalimumab biosimilar preferred. CA SB 853 protects against non-medical switching for stable patients.

Cite CA SB 853 (Continuity of Care) — protects stable patients from non-medical switches. Cite CG-DRUG-64 by name. CarelonRx exception process.

## Why Anthem Blue Cross Denies TNF Inhibitors as Experimental

An "experimental or investigational" denial from Anthem Blue Cross typically means the plan's medical policy does not recognize the specific indication, patient population, or route of administration as having sufficient evidence to meet its coverage standard — even when the FDA has approved the drug for a related condition. This can occur for off-label uses, newly approved indications not yet reflected in Anthem's policy, or when Anthem's evidence-review cycle lags behind current clinical practice.

This denial is frequently worth appealing. Anthem's experimental classification is a policy determination, not a binding medical judgment. If there is substantial peer-reviewed evidence, a current guideline recommendation from a recognized professional society, or an FDA-approved indication that matches your diagnosis, the denial can often be overturned.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial letter. Under ERISA §503 and ACA §2719, you are entitled to a full-and-fair review with access to the clinical criteria and the identity of reviewers.
• External independent review: ACA-compliant plans must offer IRO review after the internal process. The window to request external review is typically up to approximately four months from final internal denial — check your specific letter. Anthem must comply with the IRO's binding decision.
• Expedited review: Available when delay would seriously jeopardize health or ability to regain maximum function.

## Documentation to Gather

1. Diagnosis confirmation — specialist notes, biopsy or imaging results, and objective clinical findings establishing the exact diagnosis and disease stage. 2. FDA-approved labeling — print the current prescribing information showing the approved indication(s) and confirm your diagnosis falls within them. 3. Clinical severity and prior treatment — chart documentation showing disease course, prior therapies tried with dates and outcomes, and current disease-activity measures. 4. Prescriber medical-necessity letter — the clinician should state the approved indication, cite the applicable guideline organization (e.g., ACR, AAD, IBD society), and explain why this agent is the appropriate standard of care for this patient. 5. Anthem's experimental criteria — obtain the exact version of Anthem's medical policy used to deny the claim; if the denial letter does not include it, request it during the appeal.

## Criteria-Mapping Structure

| Anthem Experimental Criterion | Supporting Evidence | |---|---| | [Copy each criterion verbatim from the policy used to deny] | [FDA label page/section; guideline organization statement; peer-reviewed evidence your prescriber cites] |

For experimental denials, your prescriber's letter should: - Confirm the FDA-approved indication matches your diagnosis - Reference the applicable professional-society guideline organization and its recommendation for this drug class in your condition - Address each factor Anthem's policy lists for classifying a treatment as experimental

Never rely on remembered doses, trial statistics, or eligibility thresholds. Verify all clinical facts against the current FDA-approved prescribing label and Anthem's current published medical/coverage policy before submitting.